MA-ASTADIA
In today’s environment, many organizations have a “Cloud First” strategy for deploying business applications. Since most of the important business applications reside on mainframes, moving these applications and databases to any Cloud platform requires expert skills and technology.
The combination of Astadia’s Replatforming solutions, plus the Anubex Refactoring capabilities, offers a complete mainframe migration RoadMap. Astadia now offers all solution sets required to migrate from any IBM Z Series, or Unisys ClearPath platform, to the Cloud platform of their choosing.
“This is an exciting time to be in the Mainframe Migration business. The rapidly shrinking pool of people with mainframe software and hardware skills has given a new sense of urgency to IT buyers. The shortage of these critical skills is exacerbated by the COVID-19 Pandemic,” said Scott G. Silk, Chairman and CEO of Astadia.
“With this wave of Cloud computing, organizations are rapidly moving their applications and databases from mainframes. The Cloud enables incredible software innovation and developer productivity, access to AI and Predictive Analytics, while only charging the client for the resources they consume,” said Mr. Silk.
“Combining the forces of Astadia and Anubex leads to a unique combination of sales and delivery power with an exceptional portfolio of solutions for the migration market. This team is ready to accompany the largest organizations on their journey to the Cloud and becomes an important player in the top tier of mainframe migration companies,” said Louis Heymans, Managing Director of Anubex.
The acquisition of Anubex by Astadia allows the Anubex R&D team to continue to focus on extending their portfolio of products (CodeTurn, DataTurn, TestMatch and DataMatch) to automate refactoring and testing of legacy systems. The development of these products started well over 20 years ago, and today includes legacy technologies such as Assembler, COBOL, IDMS and Natural ADABAS that can be migrated to, among others, Java or C# in combination with all the leading SQL-databases – with the resulting applications ready for deployment in the (public) Cloud. These solutions using a Cloud-based “Migration Factory” model will be available to Astadia partners and clients worldwide.
For more details, take advantage of Astadia’s FREE Mainframe-to-Cloud Modernization Guide series, where we assist our clients as they plan and move into a safe and secure, high performance, cloud environment. This series covers IBM (NYSE:IBM) and UNISYS (NYSE:UIS) mainframes, and all popular target Cloud Platforms.
In these Mainframe-to-Cloud Migration Guides , readers will explore 20 pages of:
- Why migrate mainframe applications & databases to the Cloud?
- The challenges associated with mainframe modernization
- Detailed diagrams of mainframe software mappings to Cloud Platforms
- Programming languages & database translation tables
The Mainframe-to-Cloud Guide series is FREE , and may be downloaded.
Click on this link to view the Astadia Mainframe-to-Cloud Modernization Guide Series.
For more information visit http://www.astadia.com and follow Astadia at @AstadiaInc , Facebook/AstadiaInc , LinkedIn/Astadia
About Anubex
Anubex is an industry leader providing core software solutions, know-how, and support for complex mainframe-to-cloud migration and modernization projects.
With over 25 years of experience, demonstrated solutions and high-performing software tools, we help enterprises and government organizations boost their innovation capacity, competitiveness and agility by accelerating their digital transformation.
We are migration specialists, independent of the legacy or target technology stack. Our core competence lies in the know-how, the unique software solutions, and the extensive experience in how complex migration projects should be undertaken: what the stages and steps are, how the project should be structured, what the typical pitfalls and risks are, and how processes should be automated.
Our automated conversion and testing tools , combined with an innovative migration methodology , enable our team to support complex modernization projects and be one of the most competitive and reliable migration companies in the world.
Contacts / Headquarters
www.anubex.com
Anubex HQ
Anubex NV
Veldkant 13
2550 Kontich
Belgium
+32 3 450 42 50
migrations@anubex.com
About Astadia
Astadia is the market leading mainframe modernization consulting and systems integration boutique. A worldwide IT consulting firm, we specialize in moving IBM and Unisys mainframe applications and databases to distributed and cloud platforms. In fact, we were recently named Microsoft’s Mainframe-to-Azure partner of the year. Clients select Astadia for the following reasons: mainframe to cloud market focus, 28 years of mainframe experience, and hybrid READI methodology. Upon project completion, customers often select Astadia to manage their cloud environment as well. We have successfully completed over 200 mainframe modernization projects and are recognized industrywide as the mainframe to cloud experts.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005241/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom